SLS

SELLAS Life Sciences Group, Inc.

BS score 47.6MEDIUMPHASE2 · mkt cap $906.9M · rev ttm $0

drug hypothesis

NeuVax (E75 peptide vaccine) modulates HER2/neu protein to treat High-risk HER2+ breast cancer.

moa:HER2-targeted peptide vaccine that stimulates cytotoxic T lymphocyte (CTL) immune responses against HER2-expressing cancer cells when combined with trastuzumab and GM-CSF adjuvant

score breakdown

trial design25

base rate disconnect54

language red flags80

composite47.6

valuation analysis

market cap$906.9M

revenue ttm$0

phasePHASE2

historical base rate10%

disconnect ratio1.8x

lead trialNCT01570036

meta

cik0001390478

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase II, randomized, single-arm (non-placebo-controlled), 100 patients with high-risk HER2+ breast cancer, combination immunotherapy with NeuVax + trastuzumab + GM-CSF

primary endpoint:Invasive Disease-free Survival (DFS) from initiation of trastuzumab monotherapy through fifth year of participation

claimed differentiation

Not specified in provided filing excerpt - likely claims vaccine-induced cellular immunity provides durability advantage over antibody-based therapies like trastuzumab alone

language red flags

Filing excerpt is extremely minimal (only contains '4' in business section) - insufficient corporate disclosure provided
Trial design is single-arm without placebo control - limits interpretability of efficacy
No stated differentiation claims visible in provided data
No preclinical evidence summary provided in filing excerpt

company-stated risks

Not explicitly stated in provided filing excerpt

upcoming catalysts

December 2021 (primary completion)Phase II DFS data readout